help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2006-2874
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davenport, M. L.
Right arrow Articles by Quigley, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davenport, M. L.
Right arrow Articles by Quigley, C. A.
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Pediatric Endocrinology
Right arrow Female Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 9 3406-3416
Copyright © 2007 by The Endocrine Society

Growth Hormone Treatment of Early Growth Failure in Toddlers with Turner Syndrome: A Randomized, Controlled, Multicenter Trial

Marsha L. Davenport, Brenda J. Crowe, Sharon H. Travers, Karen Rubin, Judith L. Ross, Patricia Y. Fechner, Daniel F. Gunther, Chunhua Liu, Mitchell E. Geffner, Kathryn Thrailkill, Carol Huseman, Anthony J. Zagar and Charmian A. Quigley

University of North Carolina (M.L.D.), Chapel Hill, North Carolina 27599; Lilly Research Laboratories (B.J.C., C.L., A.J.Z., C.A.Q.), Indianapolis, Indiana 46285; The Children’s Hospital (S.H.T.), affiliated with the University of Colorado Health Sciences Center, Denver, Colorado 80218; Connecticut Children’s Medical Center (K.R.), Hartford, Connecticut 06106; Thomas Jefferson University (J.L.R.), Philadelphia, Pennsylvania 19107; Children’s Hospital Medical Center (P.Y.F., D.F.G.), Seattle, Washington 98105; The Saban Research Institute of the Children’s Hospital Los Angeles (M.E.G.), Los Angeles, California 90027; University of Arkansas for Medical Sciences (K.T.), Little Rock, Arkansas 72205; and Children’s Mercy Hospital (C.H.), Kansas City, Missouri 64108

Address all correspondence and requests for reprints to: Marsha L. Davenport, M.D., Division of Pediatric Endocrinology, University of North Carolina, CB 7039, 3341 Medical Biomolecular Research Building, Chapel Hill, North Carolina 27599-7039. E-mail: mld{at}med.unc.edu.

Context: Typically, growth failure in Turner syndrome (TS) begins prenatally, and height SD score (SDS) declines progressively from birth.

Objective: This study aimed to determine whether GH treatment initiated before 4 yr of age in girls with TS could prevent subsequent growth failure. Secondary objectives were to identify factors associated with treatment response, to determine whether outcome could be predicted by a regression model using these factors, and to assess the safety of GH treatment in this young cohort.

Design: This study was a prospective, randomized, controlled, open-label, multicenter clinical trial (Toddler Turner Study, August 1999 to August 2003).

Setting: The study was conducted at 11 U.S. pediatric endocrine centers.

Subjects: Eighty-eight girls with TS, aged 9 months to 4 yr, were enrolled.

Interventions: Interventions comprised recombinant GH (50 µg/kg·d; n = 45) or no treatment (n = 43) for 2 yr.

Main Outcome Measure: The main outcome measure was baseline-to-2-yr change in height SDS.

Results: Short stature was evident at baseline (mean length/height SDS = –1.6 ± 1.0 at mean age 24.0 ± 12.1 months). Mean height SDS increased in the GH group from –1.4 ± 1.0 to –0.3 ± 1.1 (1.1 SDS gain), whereas it decreased in the control group from –1.8 ± 1.1 to –2.2 ± 1.2 (0.5 SDS decline), resulting in a 2-yr between-group difference of 1.6 ± 0.6 SDS (P < 0.0001). The baseline variable that correlated most strongly with 2-yr height gain was the difference between mid-parental height SDS and subjects’ height SDS (r = 0.32; P = 0.04). Although attained height SDS at 2 yr could be predicted with good accuracy using baseline variables alone (R2 = 0.81; P < 0.0001), prediction of 2-yr change in height SDS required inclusion of initial treatment response data (4-month or 1-yr height velocity) in the model (R2 = 0.54; P < 0.0001). No new or unexpected safety signals associated with GH treatment were detected.

Conclusion: Early GH treatment can correct growth failure and normalize height in infants and toddlers with TS.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
B. Birgit, H. Julius, R. Carsten, S. Maryam, F. Gabriel, K. Victoria, F. Margareta, and H. Outi
Fertility Preservation in Girls with Turner Syndrome: Prognostic Signs of the Presence of Ovarian Follicles
J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 74 - 80.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
B. E. Hjerrild, K. H. Mortensen, and C. H. Gravholt
Turner syndrome and clinical treatment
Br. Med. Bull., June 1, 2008; 86(1): 77 - 93.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society